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Introduction
In 1981 Carroll et al.' introduced the dexamethasone
suppression test (DST) as a routine aid in the diag-
nosis of melancholia. Some years have since passed
and it seems useful to consider the following
questions:
(a) Is the DST a biological marker in psychiatric
diagnosis?
(b) Does the DST have a specific function as an aid in
the diagnosis of certain types of depression?
(c) What is the significance of- the DST as an
independent variable?
Definitions of biological markers will be given and
their range of applications outlined before the above
questions are discussed in detail and some consider-
ations offered. In this context the term 'vital'2 is
equated to 'endogenous', 'primary', 'major' and
'melancholic'. This is done in part because the DST
sensitivity of vital depressions can be expected to be
similar to that of depressions designated by the other
adjectives mentioned3.
Biological markers
These are indicators with the aid ofwhich behaviour
may be understood or explained. A 'trait marker' may
be permanently present regardless of the nature,
severity and course of the disease behaviour. A 'state
marker' is dependent on the phase of the disease pro-
cess and may appear in the initial phase, in the course
of or after the illness. Roughly, four groups of
markers can be distinguished.
(1) Causal markers: These indicators relate to the
pathophysiological aspects of the disease process.
The postulate is that the causal (aetiological and
pathogenetic) factors of the disease are more readily
traceable as the diagnostic significance ofthe marker
increases. With the inaccessibility of brain tissue,
psychiatric and neurobiological investigations must
of course concentrate on peripheral parameters such
as cerebrospinal fluid (CSF), blood and urine.
(2) Metabolites of the disease process: The test sub-
stance serving as marker is usually not the cause but
rather the (end-)product of the physical process. An
excess of noradrenaline (NA), for example, may be
the cause of disturbances in synaptic processes. The
NA metabolite 3-methoxy-4-hydroxyphenylethylene
glycol (MHPG) - an indicator of (increased) NA pro-
duction - is not harmfulper se. In some cases it is not
(yet) possible to establish whether the marker is
cause or consequence of the illness. An example may
be found in the enlarged ventricles (due to cerebral
atrophy) of chronic schizophrenic patients. In prin-
ciple this marker is bifunctional: it may be cause or
effect of a schizophreniform psychosis.
(3) Test markers: A metabolic disorder such as dia-
betes often cannot be diagnosed until after provo-
cation with a high-sugar diet (glucose tolerance test).
Parallel to this, psychiatry uses psychotropic sub-
stances and hormones for further investigation of
certain neurotransmitter and/or endocrine systems.
The DST could be an example of this.
(4) Genetic markers: These have no functional
relation to metabolic processes but derive their sig-
nificance from their presence on the pathogenic
chromosome. Not only are such markers - e.g. that of
colour blindness - found more often in relatives of
depressive patients, they are also represented in
other family members who are likewise ill. It may
thus be postulated that colour blindness - as a mani-
festation of a central nervous system (CNS) dysfunc-
tion - and the X-chromosome responsible for this
phenomenon, can contribute to the development of
another CNS disorder, e.g. depressive behaviour.
The DST as biological marker
Over 400 publications4 have so far reported on the use
ofthe DST as an aid in psychiatry. It may be used, for
example, as an aid in the diagnosis of disorders
of adrenal function, as in Cushing's syndrome.
Carroll et al.' found diminished suppression or non-
suppression in over 50% of the vital depressive
patients studied; in other words, in these patients the
plasma cortisol concentration returned to normal
more quickly than it did in a control group. This dem-
onstrates that, in principle, the function of the
hypothalamo-hypophyseo-adrenal axis is disturbed
in depressive patients. Non-suppression is more
likely to occur after a dose of 1 mg dexamethasone5
(at 11 pm the previous day) than after ingestion
of 1.5mg6 or 2mg'. More than 50% of the non-
suppression results were obtained in the afternoon
(4 pm); some 20% were obtained about 24 hours after
dexamethasone ingestion (at 11 pm). These studies
have led to widespread acceptance of the DST as a
biological marker in psychiatry'.
The DST in the diagnosis ofdepressive
behaviour
How specific is the DSTfor depression?
The suggestion that the DST might be a fairly
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been confirmed. Dexamethasone non-suppression has
been observed in many other psychiatric disorders3:
alcoholism, obsessive-compulsive behaviour, atypi-
cal psychoses, schizophreniform disorders, schizo-
affective psychosis7, schizophrenia, manic agitation,
dementia, borderline personality, anorexia nervosa8
and bulimia. It would not be surprising if this list
proved to be even longer.
Conceivably, the DST might be so (in)sensitive as
an indicator of a hypothalamo-hypophyseo-adrenal
axis disorder that its specificity for depression (i.e.
the percentage of suppression in non-depressive per-
sons) would be of little clinical relevance. Berger et
al.6 made more or less the same observation, although
they described it as lack of specificity of the DST for
depression. The postulate that DST non-suppression
in the case ofdisturbed behaviour is an expression of
a hypothalamo-hypophyseo-adrenal axis disorder on
a cerebral level, seems plausible. The importance of
pharmacokinetic factors9"10, such as reduced bio-
availability ofdexamethasone in the case ofDST non-
suppression, seems quite obvious. Moreover, DST
non-suppression is at least partly due to increased
serum cortisol concentrations and/or increased
dexamethasone degradation".
How specific is the DSTfor vital depression?
Carroll et al.' stressed that a disturbed DST may be
expected in some 50% of persons suspected of suffer-
ing from a vital depression (according to their
laboratory criteria, DST non-suppression exists at a
serum cortisol level > 5 #ug/dl). However convincing
this conclusion may seem, in practice DST non-
suppression may be encountered both in non-vital
depressions and in normal test subjects3. This
suggests that the so-called sensitivity ofthe DST (i.e.
the percentage ofnon-suppression in vital depressive
patients) is much lower than is desirable. Insel and
Goodwin"2 studied seven reports on DST sensitivity
assessment and concluded that the mean sensitivity
does not exceed 40%. The DST has been described
as a test of limited significance in the differential
diagnosis of vital depressions".
Our conclusion is that the DST in its present
form and mode of application has some (but as such
insufficient) significance if used alone (not combined
with other markers) as an aid in the diagnosis ofvital
depressive syndromes.
What is the DST's predictive role?
The role of the DST as a predictor of the course of
depressions and their response to therapy is rather
uncertain. Greden et al.'4 unsuccessfully attempted
to find significant differences between pre- and post-
therapeutic hypothalamo-hypophyseo-adrenal axis
variables (such as serum cortisol concentration fol-
lowing dexamethasone administration) in depressive
patients responding well to imipramine and amitrip-
tyline respectively. Non-suppression in the DST can,
however, predict a favourable response to electrocon-
vulsive therapy (ECT) if the test is done upon dis-
charge from hospital instead of six months later'5.
Greden et al.'6 performed the DST weekly and
observed normalization in most non-suppressors if
they showed a good clinical response to anti-
depressants. Targum'7 reported a similar trend: the
DST predicts whether vital depressives will improve
in response to antidepressants. However, in the case
of recurrence of non-suppression after normalization
of the test - even when patients improve in response
to antidepressant medication - there is a grave risk of
clinical relapse'4.
Peselow et al. 8 were unable to confirm whether the
DST can predict specificity of antidepressant medi-
cation. On the whole, however, the DST may be an
objective aid in research concerning the prediction
of and tolerance to antidepressant medication'3.
The fact that a DST is disturbed in vital depression
does not as such provide sufficient certainty about
the clinical course, nor an indication of the
antidepressant of choice'.
The DST as independent variable
The DST may also be studied in relation to separ-
ate symptoms-, e.g. weight loss and stress. Weight
loss is related to non-suppression in the DST in
both depressive and non-depressive patients3'9.
Ceulemans et al.'9 found DST non-suppression in the
case of preoperative stress. Zimmerman and
Ostrow20 found no indication that the Hamilton
Depression Rating Scale (HDRS) could clinically
differentiate DST suppressors and non-suppressors.
What is of interest is the relationship between
psychopathological variables (suicidal tendency,
anhedonia, mood, etc.) and the DST2'.
It seems evident that rating scales are import-
ant in treating persons with dysfunction of the
hypothalamo-hypophyseo-adrenal axis22. Mellsop
et al.23 have postulated that the degree of non-
suppression in the DST might correspond with the
degree of stress or distress of the person tested. It
seems possible that quite apart from its currently still
modest importance in the biological field, the DST
could become increasingly important in psychosocial
research in the years to come24. In behaviour re-
search, tests may assist pharmacologists, psychol-
ogists as well as medical investigators in gaining a
better understanding of human functioning as a
biopsychosocial phenomenon.
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